TY  - JOUR
AU  - Beier, Dagmar
AU  - Proescholdt, Martin
AU  - Reinert, Christiane
AU  - Pietsch, Torsten
AU  - Jones, David
AU  - Pfister, Stefan
AU  - Hattingen, Elke
AU  - Seidel, Clemens
AU  - Dirven, Linda
AU  - Luerding, Ralf
AU  - Reijneveld, Jaap
AU  - Warmuth-Metz, Monika
AU  - Bonsanto, Matteo
AU  - Bremer, Michael
AU  - Combs, Stephanie E
AU  - Rieken, Stefan
AU  - Herrlinger, Ulrich
AU  - Kuntze, Holger
AU  - Mayer-Steinacker, Regine
AU  - Moskopp, Dag
AU  - Schneider, Thomas
AU  - Beringer, Andreas
AU  - Schlegel, Uwe
AU  - Stummer, Walter
AU  - Welker, Helmut
AU  - Weyerbrock, Astrid
AU  - Paulsen, Frank
AU  - Rutkowski, Stefan
AU  - Weller, Michael
AU  - Wick, Wolfgang
AU  - Kortmann, Rolf-Dieter
AU  - Bogdahn, Ulrich
AU  - Hau, Peter
TI  - Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
JO  - Neuro-Oncology
VL  - 20
IS  - 3
SN  - 1523-5866
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DKFZ-2018-00152
SP  - 400 - 410
PY  - 2018
AB  - Medulloblastoma in adult patients is rare, with 0.6 cases per million. Prognosis depends on clinical factors and medulloblastoma entity. No prospective data on the feasibility of radiochemotherapy exist. The German Neuro-Oncology Working Group (NOA) performed a prospective descriptive multicenter single-arm phase II trial to evaluate feasibility and toxicity of radio-polychemotherapy.The NOA-07 trial combined craniospinal irradiation with vincristine, followed by 8 cycles of cisplatin, lomustine, and vincristine. Adverse events, imaging and progression patterns, histological and genetic markers, health-related quality of life (HRQoL), and cognition were evaluated. Primary endpoint was the rate of toxicity-related treatment terminations after 4 chemotherapy cycles, and the toxicity profile. The feasibility goal was reached if at least 45
LB  - PUB:(DE-HGF)16
C6  - pmid:29016837
C2  - pmc:PMC5817955
DO  - DOI:10.1093/neuonc/nox155
UR  - https://inrepo02.dkfz.de/record/132464
ER  -